Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Nektar Therapeutics (NASDAQ: NKTR)
NKTR Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-19.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
148%
NKTR Stock Analysis
NKTR
PE Ratio:
NKTR
PEG Ratio:
Not Available
NKTR
Forward EPS Growth (12 month):
0.00%
NKTR
PS Ratio:
20.8
NKTR
PSG Ratio:
-2.1
NKTR
Forward Revenue Growth (12 month):
-10.00%
NKTR Articles
No data was found